RemeGen Co

RemeGen Co Debt

The Debt of RemeGen Co (688331.SS) as of Oct 26, 2026 is 1.47 B CNY. In the previous year, Debt was 2.67 B CNY — a change of -44.97% (lower).

Debt

1.47 BCNY

YoY

-44.97%

Last updated:

In 2025, RemeGen Co's total debt was 1.47 B CNY, a -44.97% change from the 2.67 B CNY total debt recorded in the previous year.

The RemeGen Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
862.80 M CNY
Jan 1, 2019
653.45 M CNY
Jan 1, 2020
197.69 M CNY
Jan 1, 2021
102.78 M CNY
Jan 1, 2022
165.04 M CNY
Jan 1, 2023
1.26 B CNY
Jan 1, 2024
2.67 B CNY
Jan 1, 2025
1.47 B CNY
The RemeGen Co Debt history
YEARDebtYoY
1.47 BCNY-44.97%
2.67 BCNY+111.95%
1.26 BCNY+663.46%
165.04 MCNY+60.57%
102.78 MCNY-48.01%
197.69 MCNY-69.75%
653.45 MCNY-24.26%
862.80 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding RemeGen Co's Debt Structure

RemeGen Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing RemeGen Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to RemeGen Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in RemeGen Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about RemeGen Co stock

Debt of RemeGen Co is 1.47 B CNY in 2025.

Debt of RemeGen Co changed from 2.67 B CNY to 1.47 B CNY, representing a -44.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — RemeGen Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — RemeGen Co